European Low and Intermediate Risk Neuroblastoma - LINES

INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE VALENCIA0 个研究点目标入组 685 人开始时间: 2012年2月29日最近更新: 2021年11月15日

试验速览

暂无简介。

•The inclusion criterias are based on age, stage, biological characteristics, and presence of severe symptoms. The criterias are different in each treatment arm (See Protocol)
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 25
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Diagnosis of ganglioneuroma or ganglioneuroblastoma intermixed.
•For low risk neuroblastoma stage L2: Any metastatic site, MYCN amplification and age >18 months
•For low risk neuroblastoma stage Ms: Bone, pleura/lung and/or CNS metastasis, MYCN amplification and age > 12 months
•For intermediate risk neuroblastama stage L1 and INSS stage: MYCN non-amplified, INSS stages 2, 3 , 4, 4s
•For intermediate risk neuroblastama stage L2: neuroblastama NOS, MYCN amplification and age = 18 months
•For intermediate risk neuroblastama stage M: MYCN amplification and age > 12 months

发起方

INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE VALENCIA